Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

NCT03235245 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

271

Enrollment

NETWORK

Sponsor class

Conditions

Unresectable Stage III Melanoma
Stage IV Melanoma

Interventions

DRUG: Nivolumab + Ipilimumab
DRUG: Encorafenib + Binimetinib

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC